Antibacterial and anti-atrophic effects of a highly soluble, acid stable UDCA formula in Helicobacter pylori-induced gastritis

Biochemical Pharmacology

Volumn 75, Issue 11, 2008, Pages 2135-2146

  Thao, Tran Dang Hien ^a   Ryu, Ho Cheol ^a   Yoo, Seo Hong ^a   Rhee, Dong Kwon ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Helicobacter Pylori induced atrophic gastritis; Mitochondria; Reactive oxygen species; Ursodeoxycholic acid (UDCA)

Indexed keywords

ADENOSINE TRIPHOSPHATE; MALATE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE; URSODEOXYCHOLIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; ATROPHIC GASTRITIS; BODY WEIGHT; DRUG EFFECT; DRUG FORMULARY; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADENOCARCINOMA; ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOSAGE FORMS; FREE RADICAL SCAVENGERS; GASTRITIS, ATROPHIC; GENE EXPRESSION REGULATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROGEN PEROXIDE; MALATE DEHYDROGENASE; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED C57BL; NEUTROPHILS; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; STOMACH NEOPLASMS; TIME FACTORS; URSODEOXYCHOLIC ACID;

EID: 43049091168     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.03.008     Document Type: Article

References (36)

1. Peek Jr. R.M., and Crabtree J.E. Helicobacter infection and gastric neoplasia. J Pathol 208 (2006) 233-248
2. Itoh M., Wada K., Tan S., Kitano Y., Kai J., and Makino I. Antibacterial action of bile acids against Helicobacter pylori and changes in its ultrastructural morphology: effect of unconjugated dihydroxy bile acid. J Gastroenterol 34 (1999) 571-576
3. Mathai E., Arora A., Cafferkey M., Keane C.T., and O'Morain C. The effect of bile acids on the growth and adherence of Helicobacter pylori. Aliment Pharmacol Ther 5 (1991) 653-658
4. Silva J.G., Zeitune J.M., Sipahi A.M., Iryia K., and Laudanna A.A. Ursodeoxycholic acid does not interfere with in vivo Helicobacter pylori colonization. Rev Hosp Clin Fac Med Sao Paulo 55 (2000) 201-206
5. Comar K.M., and Sterling R.K. Drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 23 (2006) 207-215
6. Czaja A.J., Carpenter H.A., and Lindor K.D. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 30 (1999) 1381-1386
7. Beuers U., Spengler U., Kruis W., Aydemir U., Wiebecke B., Heldwein W., et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 16 (1992) 707-714
8. Guldutuna S., Deisinger B., Weiss A., Freisleben H.J., Zimmer G., Sipos P., et al. Ursodeoxycholate stabilizes phospholipid-rich membranes and mimics the effect of cholesterol: investigations on large unilamellar vesicles. Biochim Biophys Acta 1326 (1997) 265-274
9. Rodrigues C.M., Fan G., Ma X., Kren B.T., and Steer C.J. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 101 (1998) 2790-2799
10. Rodrigues C.M., Fan G., Wong P.Y., Kren B.T., and Steer C.J. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 4 (1998) 165-178
11. Rodrigues C.M., Ma X., Linehan-Steers C., Fan G., Kren B.T., and Steer C.J. Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation. Cell Death Differ 6 (1999) 842-854
12. Watanabe M., Houten S.M., Mataki C., Christoffolete M.A., Kim B.W., Sato H., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439 (2006) 484-489
13. Fruehauf J.P., and Meyskens Jr. F.L. Reactive oxygen species: a breath of life or death?. Clin Cancer Res 13 (2007) 789-794
14. Sohal R.S., and Weindruch R. Oxidative stress, caloric restriction, and aging. Science 273 (1996) 59-63
15. Stadtman E.R. Protein oxidation and aging. Science 257 (1992) 1220-1224
16. Wang Y., He Q.Y., Sun R.W., Che C.M., and Chiu J.F. GoldIII porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res 65 (2005) 11553-11564
17. Orr W.C., and Sohal R.S. Extension of life-span by overexpression of superoxide dismutase and catalase in Drosophila melanogaster. Science 263 (1994) 1128-1130
18. Raghavan S., Svennerholm A.M., and Holmgren J. Effects of oral vaccination and immunomodulation by cholera toxin on experimental Helicobacter pylori infection, reinfection, and gastritis. Infect Immun 70 (2002) 4621-4627
19. Haraoka M., Hang L., Frendeus B., Godaly G., Burdick M., Strieter R., et al. Neutrophil recruitment and resistance to urinary tract infection. J Infect Dis 180 (1999) 1220-1229
20. 2+ levels through the activation of non-selective cation channels induced by oxidative stress causes mitochondrial depolarization leading to apoptosis-like death in Leishmania donovani promastigotes. J Biol Chem 277 (2002) 24717-24727
21. Kwon H.Y., Ogunniyi A.D., Choi M.H., Pyo S.N., Rhee D.K., and Paton J.C. The ClpP protease of Streptococcus pneumoniae modulates virulence gene expression and protects against fatal pneumococcal challenge. Infect Immun 72 (2004) 5646-5653
22. Yarian C.S., Roroser D., and Sohal R.S. Aconitase is the main functional target of aging in the citric acid cycle of kidney mitochondria from mice. Mech Ageing Dev 127 (2006) 79-84
23. Lugli E., Troiano L., Ferraresi R., Roat E., Prada N., Nasi M., et al. Characterization of cells with different mitochondrial membrane potential during apoptosis. Cytometry A 68 (2005) 28-35
24. 2-induced apoptosis of alveolar type II cells. J Cell Biochem 94 (2005) 433-445
25. Weitzman P.D., and Danson M.J. Citrate synthase. Curr Top Cell Regul 10 (1976) 161-204
26. Bernardes-Silva C.F., Damiao A.O., Sipahi A.M., Laurindo J.R., Iriya K., Lopasso F.P., et al. Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress. Dig Dis Sci 49 (2004) 1569-1574
27. Schobitz B., Reul J.M., and Holsboer F. The role of the hypothalamic-pituitary-adrenocortical system during inflammatory conditions. Crit Rev Neurobiol 8 (1994) 263-291
28. Baracos V.E., Whitmore W.T., and Gale R. The metabolic cost of fever. Can J Physiol Pharmacol 65 (1987) 1248-1254
29. Cassells A.C., and Burke D.C. Changes in the constitutive enzymes of chick cells following infection with Semliki Forest virus. J Gen Virol 18 (1973) 135-141
30. Lincicome D.R., and McLean M.R. Host serum malic dehydrogenase activity associated with Trypanosoma lewisi infection. Exp Parasitol 20 (1967) 9-16
31. Sasahara K., Uchida Y., Matsuda K., Kawabata H., and Nishioka M. Role of energy metabolism in drug-induced acute gastric mucosal injuries in humans. J Gastroenterol Hepatol 15 (2000) 127-132
32. Saadat I., Higashi H., Obuse C., Umeda M., Murata-Kamiya N., Saito Y., et al. Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature 447 (2007) 330-333
33. Fujikawa A., Shirasaka D., Yamamoto S., Ota H., Yahiro K., Fukada M., et al. Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. Nat Genet 33 (2003) 375-381
34. Earnest D.L., Holubec H., Wali R.K., Jolley C.S., Bissonette M., Bhattacharyya A.K., et al. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 54 (1994) 5071-5074
35. Wali R.K., Stoiber D., Nguyen L., Hart J., Sitrin M.D., Brasitus T., et al. Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development. Cancer Epidemiol Biomarkers Prev 11 (2002) 1316-1321
36. Khare S., Cerda S., Wali R.K., von Lintig F.C., Tretiakova M., et al. Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer. Cancer Res 63 (2003) 3517-3523